COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
PV-10 Chemoablation of Recurrent Breast Carcinoma
Scientific title
A Phase 1 Safety and Tolerability Study of PV-10 Chemoablation of Recurrent Breast Carcinoma
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Cancer 0 0 0 0

Study type
Description of intervention(s) / exposure
Treatment: Drugs - PV-10 (rose bengal disodium 10%)

Treatment: Drugs: PV-10 (rose bengal disodium 10%)
PV-10 ablation of study lesion

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Systemic and locoregional adverse experience
Timepoint [1] 0 0
5-7 weeks post dosing (4 weeks post excision)
Secondary outcome [1] 0 0
Histopathologic response of PV-10 injected lesions
Timepoint [1] 0 0
7-21 days post dosing
Secondary outcome [2] 0 0
Wound healing of PV-10 injected lesions
Timepoint [2] 0 0
5-7 weeks post dosing (4 weeks post excision)

Key inclusion criteria
- Biopsy confirmed recurrent soft tissue breast carcinoma

- At least one measurable target lesion at least 0.5 cm and no more than 3 cm in longest

- Performance Status: Karnofsky 70-100% or ECOG 0-2

- Life Expectancy: At least 6 months

- Hematopoietic:

- White blood cell count (WBC) at least 3000/mm3

- Absolute neutrophil count (ANC) at least 1.5 (1,500/mm3)

- Hemoglobin at least 10 g/dL

- Platelet count at least 100,000/mm3

- Coagulopathy: International Normalized Ratio (INR) at least 1.5.

- Renal Function: Creatinine = 0.05-0.11 mmol/L

- Hepatic Function:

- Bilirubin = 3-21 umol/L

- AST/ALT = 3 times the upper limit of normal (ULN)

- Cardiovascular Function: No major cardiovascular disease

- Thyroid Function: T3 (serum triiodothyronine), T4 (serum thyroxine) and THS (serum
thyrotropin) within normal limits

- Immunological Function: Adequate immune system function in the opinion of the
Minimum age
18 Years
Maximum age
85 Years
Can healthy volunteers participate?
Key exclusion criteria
- Radiation therapy to study lesions within 4 weeks

- Chemotherapy or other systemic cancer therapy within 4 weeks (6 weeks for nitrosoureas
or mitomycin)

- Local treatment (e.g., surgery, cryotherapy, radiofrequency ablation) to the treatment
area within 4 weeks

- Investigational agents within 4 weeks (or 5 half-lives)

- Anti-tumor vaccine therapy within 12 weeks

- Concurrent illness:

- Severe diabetes or extremity complications due to diabetes

- Significant concurrent disease or illness, psychiatric disorders, or alcohol or
chemical dependence that would, in the opinion of the investigator, compromise
subject safety or compliance or interfere with interpretation of study results

- Thyroid autoregulatory dysfunction, including thyroid disease (subclinical or
ongoing), goiter, partial thyroidectomy, prior radioiodine- or surgically-treated
Graves' hyperthyroidism, or cystic fibrosis

- Pregnancy or fertile female subjects who are not using effective contraception, or who
are lactating

- Known or suspected brain metastases or spinal cord compression.

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Provectus Pharmaceuticals

Ethics approval
Ethics application status

Brief summary
The objective of this study is to investigate the safety of intralesional (IL) PV-10 for the
treatment of recurrent breast carcinoma. This study will also include a preliminary
assessment of response of injected lesions by histologic assessment upon lesion excision at
1-3 weeks following IL PV-10 administration. Post-excision wound healing will be assessed
clinically at 1 week and 4 weeks following excision of PV-10 injected lesions.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Eric Wachter, Ph.D.
Address 0 0
Provectus Pharmaceuticals, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications